NGS and PD-L1 expression were implemented in seek for potential benefit from immunotherapy or targeted therapy, result: Tumor Mutation Burden (TMB): 1.42Muts/Mb, Microsatellite Stability (MSS), KRAS wild type, BCL6/RPS6KA3/GATA6/TCF7L2/GNAS/FANCC/RICTOR mutation, Tumor Proportion Score (TPS): 3%, Combined Positive Score (CPS): 5%. The gene discussed is KRAS; the disease is neoplasm.